

DETECTION OF ANTI-HELICOBACTER PYLORI IgG ANTIBODIES IN HEALTHY SUBJECTS

MEHREEN AHMAD, NADEEM AFZAL, AMNA HABIB
ROMEESA TAHIR, KHURSHEED RANA AND AFIA ABBAS
Department of Immunology, University of Health Sciences, Lahore – Pakistan

ABSTRACT

Introduction: *Helicobacter pylori* (*H. pylori*) are Gram – negative microaerophilic, spiral organisms. Factors such as family history of gastric disease, source of drinking water, number of siblings, sharing beds, and level of hygiene have been linked to acquisition of *H. pylori* infection. Most of the infected people do not have clinical symptoms. The study was planned to determine the level of anti-*H. pylori* IgG antibodies in the serum of healthy individuals.

Material and Methods: The study included 80 healthy subjects and was conducted in the Department of Immunology, University of Health Sciences Lahore. The studied population was divided on the basis of (a) eating food from outside home daily, twice a week or once a week, (b) using filtered or tap water for drinking, and (c) having family history of gastric ulcer or without family history of gastric ulcer. Level of anti *H. pylori* IgG antibody was determined by ELISA technique.

Results: Among 80 asymptomatic healthy individuals anti-*H. pylori* IgG antibody was detected in 28 (35%) subjects who did not have these antibodies (p -value < 0.001). Mean level of anti-*H. pylori* IgG antibodies was 43 ± 39.3 U/ml, 30.7 ± 37.3 U/ml and 14.9 ± 19.7 U/ml in subjects eating food from outside their homes once a week, twice a week and daily respectively. Statistically significant difference was observed in the level of *H. pylori* antibodies with different eating habits ($p = 0.015$). However no statistically significant difference was observed in the level of anti-*H. pylori* antibodies between two genders, individuals using tap water and filtered water for drinking and with family history of gastric ulcer.

Conclusion: *H. pylori* IgG antibodies were present in asymptomatic healthy individuals of both the genders.

Key Words: *Helicobacter pylori*, Antibody, ELISA.

INTRODUCTION

Helicobacter pylori (*H. pylori*) are Gram – negative microaerophilic, spiral or gull – wing shaped organisms that can survive in stomach and duodenum. In 2005 Marshall and Warren received Noble prize on discovering the role of *H. pylori* in patients of gastritis and peptic ulcer disease.¹ It is the most common chronic bacterial infection which occurs worldwide but its prevalence varies among countries and even in different populations of the same country. About 80% of the individuals infected with *H. pylori* in developing countries and about 50% in the developed countries are asymptomatic. Only 10% to 20% of *H. pylori* infected individuals develop gastric hyperacidity and peptic ulcer. *H. pylori* infection varies widely by geographical area, age, race, and socioeconomic status.^{2,3}

Exact mode of transmission is not known but housing cluster, overcrowding, number of siblings, sharing beds, level of hygiene, family history of gastric disease, and source of drinking water; have been linked to acquisition of *H. pylori*. The organism has

been cultured from stool samples of infected children and adults therefore, probably the organism is transmitted by fecal – oral route.^{2,4,5}

Strong humoral and cellular immune response is mounted against *H. pylori*. Normal gastric acidity and its peristaltic movements inhibit bacterial colonisation but *H. pylori* can evade defense mechanisms and establish infection that may persist for lifetime in the host. Survival of *H. pylori* in acidic stomach is dependent on urease which is an important virulence factor for gastritis² along with cag pathogenicity island (cag PAI) vacuolation cytotoxin, and cytotoxin associated gene A (Cag A) protein.^{6,7} *H. pylori* also evade immune system by producing enzyme arginase which prevents nitric oxide (NO) production and therefore, it can survive within macrophages by interfering with lysosomal proteins.⁸ The organism also evades adaptive immune response by virulent factor (Vac A) which blocks antigen dependent proliferation of T – cells.⁹ Lipopolysaccharides (LPS) an flagellin (Fla A) of Gram negative bacteria activate TLR 4 and TLR5 respectively but

LPS and Fla A of *H. pylori* are 100 – 1000 TLR assist in evasion of immune system.¹⁰

Laboratory techniques for the detection of *H. pylori* include both invasive and non-invasive methods. Invasive methods include rapid urease test, histological identification and culture of the organism from gastric biopsy. Non-invasive methods are urease breath test, serological tests, detection of *H. pylori* stool antigen (HpSA) and *H. pylori* antibodies in urine and saliva.¹¹ Urease breath test has advantages over serological analysis, but is expensive and time – consuming whereas serological techniques offer high sensitivity and specificity. It has been suggested that serological diagnosis was sufficient to detect *H. pylori* infection and it should be replaced by endoscopy – based procedures. Generally non-invasive tests are used for screening *H. pylori* in healthy population.¹²⁻¹⁴ Therefore, a study was planned to determine the level of *anti-H. pylori* IgG antibodies in the serum of healthy individuals and ELISA method was used for this purpose.

MATERIAL AND METHODS

It was an observational cross sectional study conducted at the Department of Immunology, University of Health Sciences Lahore during February 2010 – September 2010. It included 80 healthy subjects and the studied population was divided on the basis of (a) eating food from outside home daily, twice a week or once a week, (b) using filtered or tap water for drinking, and (c) having family history of gastric ulcer or without family history of gastric ulcer. Level of *H. pylori* IgG antibody was determined by ELISA technique using quantitative immunoassay kit from Bio check, Inc (U.S.A).

Statistical Analysis

The data was entered and analysed using Statistical Package for Social Sciences 16 (SPSS – 16). Mean \pm SD was given for quantitative variables. Frequencies, percentages and graphs were given for qualitative variables. Two independent sample *t* test was applied to observe group mean differences. A *p-value* of equivalent to < 0.05 was considered statistically significant.

RESULTS

Eighty (80) healthy subjects included in this study comprised of 31 (38%) males and 49 (64%) females. *Anti-H. pylori* IgG antibodies were detected in 28 (35%) subjects while 52 (65%) subjects did not have these antibodies in the serum (Fig. 1). Subjects with *anti-H. pylori* IgG antibodies had their mean level of 71 ± 30 U/ml and it was 8.9 ± 4.1 U/ml in subjects who did have these antibodies. The difference in the level of *anti-H. pylori* IgG antibodies between these groups was statistically significant ($p = 0.001$)

(Table 1). The level of *anti-H. pylori* IgG antibodies among males and females was 38.7 ± 40.5 U/ml and 25.7 ± 31.3 U/ml respectively, the difference in the level of *anti-H. pylori* IgG antibodies between these groups was not statistically significant ($p = 0.11$) (Table 2).




Fig. 1: Frequency of *anti-H. pylori* IgG antibodies in healthy subjects.

Table 1: Number, mean and comparison of *anti-H. pylori* antibodies in healthy individuals.

Antibody present Mean \pm SD (n = 28)	Antibody absent Mean \pm SD (n = 52)	p-value
71.4 \pm 32 U/ml	8.90 \pm 4.14 U/ml	< 0.001

n = number of patients; *p-value* < 0.05 = significant

Table 2: Number, mean and comparison of *anti-H. pylori* antibodies in healthy individuals between two genders.

Males Mean \pm SD (n = 31)	Females Mean \pm SD (n = 49)	p-value
38.7 \pm 40.5 U/ml	27.5 \pm 31.3 U/ml	0.11

n = number of patients; *p-value* < 0.05 = significant

Mean level of *anti-H. pylori* IgG antibodies was 43 ± 39.3 U/ml, 30.7 ± 37.3 U/ml and 14.9 ± 19.7 U/ml in participants who used to eat once a week, twice a week and daily from outside home respectively. Statistically significant difference was observed in the level of *H. pylori* antibodies among individuals with different eating habits ($p = 0.015$) (Table 3). By applying post Hoc test statistically significant difference was observed in the level of *H. pylori* antibodies among participants who were eating from outside home once a week ($p = 0.011$). No statistically significant difference was observed bet-

ween individuals using tap water or filtered water for drinking ($p = 0.701$). Among participants with family history of gastric ulcer, mean level of *H. pylori* antibodies was 30.2 ± 31.9 U/ml and it was 30.9 ± 36.6 U/ml who did not have family history of gastric ulcer. The difference in the level of *anti-H. pylori* IgG antibodies between these two groups was not statistically significant ($p = 0.948$).

Table 3: Number, mean and comparison of *anti-H. pylori* antibodies in healthy individuals with eating habits.

Once a week Mean \pm SD (n = 30)	Twice a week Mean \pm SD (n = 27)	Daily Mean \pm SD (n = 23)	p-value
43.05 \pm 39.3 U/ml	30.7 \pm 37.3 U/ml	14.90 \pm 19.7 U/ml	< 0.001

n = number of patients; p-value < 0.05 = significant

DISCUSSION

In the present study, among 80 healthy subjects *Anti-H. pylori* IgG antibodies were detected in 28 (38%) subjects. The present study is not in agreement with Bakka *et al*¹⁵ who documented *anti-H. pylori* IgG antibodies in 66% of healthy subjects in the same age group. Studies showed variation in the prevalence of *anti-H. pylori* IgG antibodies in different parts of the world such as Rodrigues *et al*¹⁶ found 77% in Brazil, Gracia *et al*¹⁶ documented 17% in Orense, and Kirn *et al*¹⁸ showed 46% in South Korea among healthy individuals.

In the present study there was no statistical significant difference in the level of *anti-H. pylori* IgG antibodies in two genders. Our findings are similar to the studies of Bakka *et al*,¹⁵ Rodrigues *et al*¹⁶ and Kirn *et al*¹⁸ who also could not find statistically significant difference in the level of *H. pylori* IgG antibodies in both the genders. In the present study the difference in the level of *anti-H. pylori* IgG antibodies between the participants who were using tap water or filtered water for drinking was not statistically significant ($p = 0.701$). The findings of Lin *et al*¹⁹ was similar to the present study because he also could not find statistically significant difference in the level of *anti-H. pylori* IgG antibodies among people who used tap water and river or well water for drinking but Nurgalieva *et al*²⁰ linked drinking river water with high risk of *H. pylori* infection as compared to tap water.

In the present study, mean antibody level of *anti-H. pylori* IgG antibodies was 30.17 ± 31.9 U/ml and 30.9 ± 36.6 U/ml in subjects having family history of gastric ulcer and those who did not have such family history respectively and the difference in the level of *anti-H. pylori* IgG antibodies between

these groups was not statistically significant. Escobar²² *et al* reported high level of *anti-H. pylori* antibody in subjects with family history of peptic ulcer disease as compared to those who did not have such family history. Salih²¹ *et al* found that children of mothers with gastric ulcer were at a greater risk of acquiring *H. pylori* infection and he suggested through physical contact mothers transmit *H. pylori* to their children.

In the present study, statistically significant difference was observed in the level of *H. pylori* antibodies among individuals with different eating habits ($p = 0.015$). Beguc *et al*²³ documented increased prevalence of *H. pylori* infection in individuals who consumed food from street vendors and he supported that food prepared under unhygienic conditions as a source of transmission of this infection. On the other hand the study of Duynhove *et al*²⁴ documented no direct evidence of food in the transmission of *H. pylori*.

It is concluded that *anti-H. pylori* IgG antibodies were found in asymptomatic healthy individuals of both genders.

ACKNOWLEDGEMENTS

The authors are grateful to the V.C of UHS for financially helping the project.

REFERENCES

1. Per M Hellstrom. This year's Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of *Helicobacter pylori* as pathogen in the gastrointestinal tract. *World J Gastroenterol* 2006; 12: 3126-27.
2. Cehlay C, Peraz GI. Immune responses to *Helicobacter pylori* colonisation mechanisms and clinical outcomes. *ClinSci* 2006; 110: 305-14.
3. Rothenbacher D, Brenner H. Burden of *Helicobacter pylori* and *H. pylori*-related diseases in developed countries : recent developments and future implications. *Microbes and Infection* 2003; 5: 693-703.
4. Brown LM. *Helicobacter pylori* : epidemiology and routes of transmission. *Epidemiol Rev* 2000; 22: 283-97.
5. Kabir S. Detection of *Helicobacter pylori* in feces by culture, PCR and enzyme immunoassay. *J Med Microbiol* 2001; 50: 1021-29.
6. Szczepanik M. Interplay between *H. pylori* and the immune system. *J Physiol Phannacol* 2006; 57: 15-27.
7. Prinz C, Hafsi N, Volland P. *Helicobacter pylori* virulence Factors, host immune response and implications for therapeutic vaccination. *Trends Microbiol* 2003; 11: 135.
8. Ramarao N, Meyer TF. *Helicobacter pylori* resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence activated cell sorting. *Infect Immun* 2001; 69: 2604-11.
9. Boncristiano, Paccani M, Barone SR, Ulivieri C, Patrusi I., liver D, Amedei A, Rlios M, *et al*. The *Helico-*

- bacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J Exp Med* 2003; 198: 1887-1897.
10. Gewirtz AT, YuY, Krishna US, Israel DA, Lyons SL and Peek R M. *Helicobacter pylori* flagellin evades toll – like receptor 5-mediated innate immunity. *J Infect Dis* 2004; 189: 1914-20.
 11. Meurer LN, Bower DJ. Management of *Helicobacter pylori* Infection. *Am Fam Physician* 2002; 65: 1327-36.
 12. Andersen LP, Raskov H-H, Elsborg L. Prevalence of antibodies against heat stable antigens from *Helicobacter pylori* in patients with dyspeptic symptoms and normal persons *APMIS* 1992; 100: 779-89.
 13. Andersen LP, Espersen F, Souckov A. Isolation and preliminary evaluation of a low – molecular – mass antigen preparation for improved detection of *Helicobacter pylori* immunoglobulin G antibodies. *Clin Diagn Lab Immunol* 1995; 2: 156-9.
 14. Jensen AKV, Andersen LP, Wachmann CH. Evaluation of eight commercial kits for *Helicobacter pylori* IgG antibody detection. *APMIS* 1993; 10: 795-801.
 15. Bakka AS, Salih BA. Prevalence of *Helicobacter pylori* infection in asymptomatic subjects in Libya. *Diagn Microbiol Infect Dis* 2002; 43: 265-68.
 16. Rodrigues MN, Queiroz DM, Rodrigues RT, Rocha A M C, Luz C.R, Braga L.L.B. Prevalence of *Helicobacter pylori* infection in Fortaleza, Northeastern Brazil. *Rev saude publica* 2005; 39: 847-49.
 17. Garcia RM, Diz PG, Benavides RAS, Seara JF. Prevalence of *Helicobacter pylori* infection in the general adult population of the province of Ourense. *Rev esp enferm dig* 2006; 98: 241-48.
 18. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, Kim J.I et al. Seroprevalence study of *Helicobacter pylori* infection in asymptomatic people in South Korea. *J Gastroenterol Hepatol* 2001; 16: 969-75.
 19. Lin. D, Lin J, Chen C, Chen S, Chen W. Seroprevalence of *Helicobacter pylori* Infection Among School children and Teachers in Taiwan. 2007; 12: 258-64.
 20. Nurgalieva Z, Malaty H.M, Graham D.Y, Almuchambetova. R, Machmudova.A, Kapsultanova.D, et al. *Helicobacter pylori* infection in Kazakhstan: effect of water source and household hygiene. *Am J Trop Med Hyg* 2002; 67: 201-6.
 21. Salih B.A., *Helicobacter pylori* infection in developing countries. The burden for how long *saudi journal of gastrology* 2009; 15: 201-7.
 22. Eccobar ML, Kawakami E. Evidence of mother to child transmission of *Helicobacter pylori* infection. *Arq Gastroenterol* 2004; 41: 239-44.
 23. Begue RE, Gonzales JL, Gracian AC, Tang SC. Dietary factor associated with transmission of *Helicobacter* in Lima. *Am J Trop Med Hyg* 1998; 59: 637-40.
 24. Duynhoven YTHP, Jonge R. Transmission of *Helicobacter pylori*: a role for food. *World Health Organization* 2001; 79: 455-60.